Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.

S'inscrire

AUTL Autolus Therapeutics PLC

4,55

0,56 (14,04%)

01 Juin 2024 - Fermé

Retardé de 15 minutes

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

null

Autolus Therapeutics (NASDAQ:AUTL)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024

Plus de graphiques de la Bourse Autolus Therapeutics

Autolus Therapeutics (NASDAQ:AUTL)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024

Plus de graphiques de la Bourse Autolus Therapeutics

Actualités Autolus Therapeutics PLC

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
Vendredi 31 Mai 2024 ( il y a 1 jour) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Vendredi 17 Mai 2024 ( il y a 2 semaines) • Edgar (US Regulatory)

Form 8-K - Current report
Vendredi 17 Mai 2024 ( il y a 2 semaines) • Edgar (US Regulatory)

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
Vendredi 17 Mai 2024 ( il y a 2 semaines) • GlobeNewswire Inc.

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
Mardi 14 Mai 2024 ( il y a 3 semaines) • GlobeNewswire Inc.

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB
Lundi 13 Mai 2024 ( il y a 3 semaines) • Edgar (US Regulatory)

Form 8-K - Current report
Lundi 13 Mai 2024 ( il y a 3 semaines) • Edgar (US Regulatory)

Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
Lundi 13 Mai 2024 ( il y a 3 semaines) • GlobeNewswire Inc.

Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
Mercredi 24 Avril 2024 ( il y a 1 mois) • GlobeNewswire Inc.

Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
Mardi 23 Avril 2024 ( il y a 1 mois) • GlobeNewswire Inc.

Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL
Mardi 2 Avril 2024 ( il y a 2 mois) • GlobeNewswire Inc.

Autolus Therapeutics Announces Changes to its Board of Directors
Lundi 1 Avril 2024 ( il y a 2 mois) • GlobeNewswire Inc.

Plus d'articles sur Autolus Therapeutics PLC

Vontobel Financial Produ...

BNP Paribas Issuance

Prospector Metals (QB)

Merrill Lynch Ftse100 Stppd G&i

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales